Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

Back to Search
Print
Bookmark Trial

NCT00782600

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).

- Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs). A BMI lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion.

- An informed consent document signed and dated by the subject or a legally acceptable representative.

- Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal
allergies at time of dosing) disease or clinical findings at screening.


- Any conHistory of regular alcohol consumption exceeding 7 drinks/week for females or
14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.


- condition possibly affecting drug absorption (eg, gastrectomy).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Rheumatoid ArthritisStudy Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis NCT00141830
  1. Largo, Florida
  2. Palm Harbor, Florida
  3. Sarasota, Florida
  4. Boise, Idaho
  5. Kansas City, Kansas
  6. Frederick, Maryland
  7. Albuquerque, New Mexico
  8. Charlotte, North Carolina
  9. Duncansville, Pennsylvania
  10. Austin, Texas
  11. Dallas, Texas
  12. San Antonio, Texas
  13. Spokane, Washington
  14. La Crosse, Wisconsin
  15. Penticton, British Columbia
  16. Newmarket, Ontario
  17. Toronto, Ontario
  18. Montréal, Quebec
  19. Trois-Rivières, Quebec
  20. Saskatoon, Saskatchewan
  21. Quebec,
  22. Budapest,
  23. Békéscsaba,
  24. Veszprém,
  25. Brescia,
  26. Genova,
  27. Pavia,
  28. Roma,
  29. Siena,
  30. Jalisco, Guadalajara
  31. Delegacion Cuahutemoc,
  32. Andalucia,
  33. Castilla la Mancha,
  34. Comunidad Valenciana,
  35. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisStudy Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550 NCT01059864
  1. Birmingham, Alabama
  2. Huntsville, Alabama
  3. Gilbert, Arizona
  4. Scottsdale, Arizona
  5. Upland, California
  6. Jacksonville, Florida
  7. Dayton, Ohio
  8. Mayfield Village, Ohio
  9. Greenville, South Carolina
  10. Allen, Texas
  11. Seoul,
  12. Seoul,
  13. Seoul,
  14. Seoul,
  15. Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisEffects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA) NCT01164579
  1. Gilbert, Arizona
  2. Huntington Beach, California
  3. Upland, California
  4. Ormond Beach, Florida
  5. Pinellas Park, Florida
  6. St. Petersburg, Florida
  7. Oklahoma City, Oklahoma
  8. Allen, Texas
  9. Buenos Aires,
  10. Buenos Aires,
  11. Buenos Aires,
  12. Valdivia, Region XIV
  13. Osorno, X Region
  14. Split,
  15. Zagreb,
  16. Hostivice,
  17. Praha 11 - Chodov,
  18. Praha 1,
  19. Praha 1,
  20. Praha 2,
  21. Uherske Hradiste,
  22. Zlin,
  23. Zlin,
  24. Balatonfured,
  25. Budapest,
  26. Budapest,
  27. Debrecen,
  28. Gyor,
  29. Mexico, D. F.
  30. Mexico, D.f.
  31. Mexico, Distrito Federal
  32. Chapultepec,
  33. Chihuahua,
  34. Mexico D.F.,
  35. San Luis Potosi,
  36. Bialystok,
  37. Poznan,
  38. Torun,
  39. San Juan,
  40. San Juan,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Rheumatoid ArthritisThree Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks NCT00147498
  1. Upland, California
  2. Clearwater, Florida
  3. Miami, Florida
  4. New Port Richey, Florida
  5. Ocala, Florida
  6. Orlando, Florida
  7. Port Richey, Florida
  8. Tampa, Florida
  9. Dubuque, Iowa
  10. Dubuque, Iowa
  11. Concord, New Hampshire
  12. Plainview, New York
  13. Charlotte, North Carolina
  14. Hickory, North Carolina
  15. Hickory, North Carolina
  16. Dayton, Ohio
  17. Ducansville, Pennsylvania
  18. Johnstown, Pennsylvania
  19. Charleston, South Carolina
  20. Columbia, South Carolina
  21. Nashville, Tennessee
  22. Dallas, Texas
  23. Everett, Washington
  24. Tacoma, Washington
  25. Gent,
  26. Goiânia, GO
  27. Goiânia, GO
  28. Curitiba, PR
  29. São Paulo, SP
  30. São Paulo, SP
  31. Edmonton, Alberta
  32. Victoria, British Columbia
  33. Saint John's, Newfoundland and Labrador
  34. London, Ontario
  35. Toronto, Ontario
  36. Berlin,
  37. Dresden,
  38. Hamburg,
  39. Hildesheim,
  40. Leipzig,
  41. Muenchen,
  42. Neubrandenburg,
  43. Wiesbaden,
  44. Firenze,
  45. Genova,
  46. Pavia,
  47. México, D.f.
  48. Tlalpan Seccion 16, DF
  49. Guadalajara, Jalisco
  50. Aguascalientes,
  51. San Luis Potosí,
  52. Kosice,
  53. Piestany,
  54. Zilina,
  55. L´hospitalet de Llobregat, Barcelona
  56. Santiago de Compostela, La Coruña
  57. Barcelona,
  58. Guadalajara,
  59. Madrid,
  60. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers
Official Title  ICMJE A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers
Brief Summary This study is to test the idea that a controlled release formulation of CE-224,535 may allow for less frequent dosing and exposure to lower levels of drug than an immediate release formulation.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Rheumatoid Arthritis
Intervention  ICMJE
  • Drug: suspension IR
    50 mg IR suspension once daily for one day
  • Drug: CR 1
    50 mg shorter release CR once daily for one day
  • Drug: CR 2
    50 mg medium release CR once daily for one day
  • Drug: CR 3
    longer release SR formulation once daily for one day
Study Arms  ICMJE
  • Experimental: 50 mg oral suspension
    once daily for one day
    Intervention: Drug: suspension IR
  • Experimental: 50 mg CR Type 1
    once daily for one day
    Intervention: Drug: CR 1
  • Experimental: 50 mg CR Type 2
    once daily for one day
    Intervention: Drug: CR 2
  • Experimental: 50 mg SR Type 3
    once daily for one day
    Intervention: Drug: CR 3
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 29, 2008)		16
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE August 2008
Actual Primary Completion Date August 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
  • Body Mass Index (BMI) of 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs). A BMI lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion.
  • An informed consent document signed and dated by the subject or a legally acceptable representative.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
  • Any conHistory of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
  • condition possibly affecting drug absorption (eg, gastrectomy).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00782600
Other Study ID Numbers  ICMJE A6341011
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP